{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:04:53Z","timestamp":1761919493463},"reference-count":49,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Among hematologic neoplasms, chronic myeloid leukemia (CML) is exquisitely sensitive to graft-versus-leukemia (GVL) because patients relapsing after allogeneic hematopoietic stem-cell transplantation (alloHSCT) can be cured by donor leukocyte infusion (DLI); however, the cellular mechanisms and strategies to separate GVL from GVHD are unclear. We used a BCR-ABL1 transduction\/transplantation mouse model to study the mechanisms of DLI in MHC-matched, minor histocompatibility antigen\u2013mismatched allogeneic chimeras with CML-like leukemia, in which DLI can be administered at the time of transplantation (early) or after recovery of hematopoiesis (delayed). After early DLI, CML-like leukemia cannot be transferred into immunocompetent secondary recipients as soon as 4 days after primary transplantation, demonstrating that cotransplantation of T lymphocytes blocks the engraftment of BCR-ABL1\u2013transduced stem cells. In contrast, in allogeneic chimeras with established CML-like leukemia, combined treatment with delayed DLI and the kinase inhibitor imatinib eradicates leukemia with minimal GVHD. The GVL effect is directed against minor histocompatibility antigens shared by normal and leukemic stem cells, and is mediated predominantly by CD8+ T cells, with minor contributions from CD5\u2212 splenocytes, including natural killer cells. These results define a physiologic model of adoptive immunotherapy of CML that will be useful for investigating the cellular and molecular mechanisms of GVL.<\/jats:p>","DOI":"10.1182\/blood-2011-01-331009","type":"journal-article","created":{"date-parts":[[2011,11,10]],"date-time":"2011-11-10T04:12:08Z","timestamp":1320898328000},"page":"273-284","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model"],"prefix":"10.1182","volume":"119","author":[{"given":"Yi-Fen","family":"Lu","sequence":"first","affiliation":[{"name":"Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA;"},{"name":"Graduate Program in Immunology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Cristina","family":"Gavrilescu","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Betancur","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Lazarides","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Klingemann","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Tufts Medical Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Van Etten","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Tufts Medical Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"8","key":"2019111719491897700_B1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia.","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111719491897700_B2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0037-1963(03)70043-2","article-title":"Allogeneic stem cell transplantation for chronic myeloid leukemia.","volume":"40","author":"Barrett","year":"2003","journal-title":"Semin Hematol"},{"issue":"3","key":"2019111719491897700_B3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation.","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"12","key":"2019111719491897700_B4","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"issue":"2","key":"2019111719491897700_B5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJM199401133300204","article-title":"Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.","volume":"330","author":"Porter","year":"1994","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111719491897700_B6","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"issue":"2","key":"2019111719491897700_B7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111719491897700_B8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2003-02-0342","article-title":"Graft-versus-leukemia reactions in allogeneic chimeras.","volume":"103","author":"Kolb","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111719491897700_B9","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"issue":"11","key":"2019111719491897700_B10","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood.V86.11.4337.bloodjournal86114337","article-title":"CD8-depleted donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: graft vs. leukemia without graft vs. host disease.","volume":"86","author":"Giralt","year":"1995","journal-title":"Blood"},{"issue":"10","key":"2019111719491897700_B11","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V91.10.3671","article-title":"Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.","volume":"91","author":"Alyea","year":"1998","journal-title":"Blood"},{"issue":"11","key":"2019111719491897700_B12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111719491897700_B13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111719491897700_B14","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111719491897700_B15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111719491897700_B16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111719491897700_B17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111719491897700_B18","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2019111719491897700_B19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2009.05.002","article-title":"Current role of stem cell transplantation in chronic myeloid leukaemia.","volume":"22","author":"Gratwohl","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111719491897700_B20","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.3816\/CLM.2009.s.021","article-title":"Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.","volume":"9","author":"Champlin","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"13","key":"2019111719491897700_B21","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1182\/blood-2004-06-2229","article-title":"Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model.","volume":"104","author":"Krause","year":"2004","journal-title":"Blood"},{"issue":"11","key":"2019111719491897700_B22","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2003-10-3735","article-title":"Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T cell killing.","volume":"103","author":"Matte","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2019111719491897700_B23","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.","volume":"189","author":"Li","year":"1999","journal-title":"J Exp Med"},{"issue":"2","key":"2019111719491897700_B24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/mrd.1081","article-title":"Rapid DNA extraction and PCR-sexing of mouse embryos.","volume":"60","author":"McClive","year":"2001","journal-title":"Mol Reprod Dev"},{"issue":"6744","key":"2019111719491897700_B25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/35004599","article-title":"A clonogenic common myeloid progenitor that gives rise to all myeloid lineages.","volume":"404","author":"Akashi","year":"2000","journal-title":"Nature"},{"issue":"5947","key":"2019111719491897700_B26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/307168a0","article-title":"Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts.","volume":"307","author":"Ildstad","year":"1984","journal-title":"Nature"},{"issue":"12","key":"2019111719491897700_B27","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1073\/pnas.87.12.4595","article-title":"Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity.","volume":"87","author":"Lapidot","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2019111719491897700_B28","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1182\/blood-2007-11-125294","article-title":"CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.","volume":"111","author":"Matte-Martone","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111719491897700_B29","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","article-title":"Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow.","volume":"92","author":"Pear","year":"1998","journal-title":"Blood"},{"issue":"8","key":"2019111719491897700_B30","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1182\/blood-2003-05-1550","article-title":"Evidence for a positive role of SHIP in BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia.","volume":"102","author":"Jiang","year":"2003","journal-title":"Blood"},{"issue":"45","key":"2019111719491897700_B31","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.","volume":"103","author":"Hu","year":"2006","journal-title":"Proc Natl Acad SciU S A"},{"issue":"5","key":"2019111719491897700_B32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.","volume":"36","author":"Hu","year":"2004","journal-title":"Nat Genet"},{"issue":"13","key":"2019111719491897700_B33","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.","volume":"110","author":"Olavarria","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111719491897700_B34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bmt.1705167","article-title":"Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.","volume":"36","author":"Savani","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111719491897700_B35","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood-2004-09-3534","article-title":"PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.","volume":"105","author":"Wolff","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2019111719491897700_B36","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1182\/blood-2003-02-0438","article-title":"The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia.","volume":"103","author":"Cook","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2019111719491897700_B37","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/01.TP.0000164500.16052.3C","article-title":"Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor.","volume":"79","author":"Elmaagacli","year":"2005","journal-title":"Transplantation"},{"issue":"13","key":"2019111719491897700_B38","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1016\/j.molimm.2008.04.016","article-title":"KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.","volume":"45","author":"van der Meer","year":"2008","journal-title":"Mol Immunol"},{"issue":"8","key":"2019111719491897700_B39","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"issue":"9166","key":"2019111719491897700_B40","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)11135-2","article-title":"Mixed lymphohematopoietic chimerism and graft-versus-lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone marrow transplantation.","volume":"353","author":"Sykes","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"2019111719491897700_B41","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.4049\/jimmunol.180.5.3260","article-title":"Regulation of the NK cell alloreactivity to bone marrow cells by the combination of the host NK gene complex and MHC haplotypes.","volume":"180","author":"Iizuka","year":"2008","journal-title":"J Immunol"},{"key":"2019111719491897700_B42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/978-0-387-78580-6_20","article-title":"Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation.","volume":"144","author":"Porter","year":"2009","journal-title":"Cancer Treat Res"},{"issue":"9","key":"2019111719491897700_B43","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm1089","article-title":"Donor APCs are required for maximal GVHD but not for GVL.","volume":"10","author":"Matte","year":"2004","journal-title":"Nat Med"},{"issue":"1","key":"2019111719491897700_B44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI17601","article-title":"Memory CD4+ T cells do not induce graft-versus-host disease.","volume":"112","author":"Anderson","year":"2003","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111719491897700_B45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nm0602-575","article-title":"Acute graft-versus-host disease does not require alloantigen expression on host epithelium.","volume":"8","author":"Teshima","year":"2002","journal-title":"Nat Med"},{"issue":"11","key":"2019111719491897700_B46","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1182\/blood.V75.11.2250.2250","article-title":"Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.","volume":"75","author":"Hauch","year":"1990","journal-title":"Blood"},{"issue":"10","key":"2019111719491897700_B47","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2005-02-0479","article-title":"The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.","volume":"106","author":"Sconocchia","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2019111719491897700_B48","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/sj.leu.2404892","article-title":"Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.","volume":"21","author":"Savani","year":"2007","journal-title":"Leukemia"},{"issue":"5562","key":"2019111719491897700_B49","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/1\/273\/1347835\/zh800112000273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/1\/273\/1347835\/zh800112000273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:49:42Z","timestamp":1574038182000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/1\/273\/125740\/Distinct-graftversusleukemic-stem-cell-effects-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,5]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-01-331009","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,5]]}}}